Christopher N. Selverian

Christopher N. Selverian

Auto-generated profile, based on publicly available information

Christopher N. Selverian

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2021 in Nature Immunology
Verified
Journal Article
Open access
PDF file
VDVincent Dussupt
Vincent Dussupt
RSRajeshwer S. Sankhala
Rajeshwer S. Sankhala
LMLetzibeth Mendez-Rivera
Letzibeth Mendez-Rivera
STSamantha M. Townsley
Samantha M. Townsley
FSFabian Schmidt
Fabian Schmidt
SKShelly J. Krebs
Shelly J. Krebs
Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent neutralizing antibodies directed against either the N-terminal domain (NTD) or the receptor-binding domain (RBD) of the spike protein. Administered in combinations, these mAbs provided low-dose protection against SARS-CoV-2 infection in the K18-human angiotensin-converting enzyme 2 mouse model, using both neutralization and Fc effector antibody functions. The RBD mAb WRAIR-2125, which targets residue F486 through a unique heavy-chain and light-chain pairing, demonstrated potent neutralizing activity against all major SARS-CoV-2 variants of concern. In combination with NTD and other RBD mAbs, WRAIR-2125 also prevented viral escape. These data demonstrate that NTD/RBD mAb combinations confer potent protection, likely leveraging complementary mechanisms of viral inactivation and clearance.

12 February 2025 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
Riccardo VernuccioRiccardo Vernuccio
Riccardo Vernuccio
ALAlejandro Martínez León
Alejandro Martínez León
Chetan PoojariChetan Poojari
Chetan Poojari
JBJulian Buchrieser
Julian Buchrieser
CSChristopher N. Selverian
Christopher N. Selverian
Pablo Guardado-CalvoPablo Guardado-Calvo
Pablo Guardado-Calvo
Mpox is a zoonotic disease endemic to Central and West Africa. Since 2022, two human-adapted monkeypox virus (MPXV) strains have caused large outbreaks outside these regions. Tecovirimat is the most widely used drug to treat mpox. It blocks viral egress by targeting the viral phospholipase F13; however, the structural details are unknown, and mutations in the F13 gene can result in resistance against tecovirimat, raising public health concerns. Here we report the structure of an F13 homodimer using X-ray crystallography, both alone (2.1 Å) and in complex with tecovirimat (2.6 Å). Combined with molecular dynamics simulations and dimerization assays, we show that tecovirimat acts as a molecular glue that promotes dimerization of the phospholipase. Tecovirimat resistance mutations identified in clinical MPXV isolates map to the F13 dimer interface and prevent drug-induced dimerization in solution and in cells. These findings explain how tecovirimat works, allow for better monitoring of resistant MPXV strains and pave the way for developing more potent and resilient therapeutics.

1 June 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NSNaveenchandra Suryadevara
Naveenchandra Suryadevara
ASAndrea R. Shiakolas
Andrea R. Shiakolas
LVLaura A. VanBlargan
Laura A. VanBlargan
EBElad Binshtein
Elad Binshtein
RCRita E. Chen
Rita E. Chen
JCJames E. Crowe
James E. Crowe
The protective human antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) focuses on the spike (S) protein, which decorates the virion surface and mediates cell binding and entry. Most SARS-CoV-2 protective antibodies target the receptor-binding domain or a single dominant epitope (“supersite”) on the N-terminal domain (NTD). Using the single B cell technology called linking B cell receptor to antigen specificity through sequencing (LIBRA-Seq), we isolated a large panel of NTD-reactive and SARS-CoV-2–neutralizing antibodies from an individual who had recovered from COVID-19. We found that neutralizing antibodies against the NTD supersite were commonly encoded by the IGHV1-24 gene, forming a genetic cluster representing a public B cell clonotype. However, we also discovered a rare human antibody, COV2-3434, that recognizes a site of vulnerability on the SARS-CoV-2 S protein in the trimer interface (TI) and possesses a distinct class of functional activity. COV2-3434 disrupted the integrity of S protein trimers, inhibited the cell-to-cell spread of the virus in culture, and conferred protection in human angiotensin-converting enzyme 2–transgenic (ACE2-transgenic) mice against the SARS-CoV-2 challenge. This study provides insight into antibody targeting of the S protein TI region, suggesting this region may be a site of virus vulnerability.

18 October 2024 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
CSChristopher N Selverian
Christopher N Selverian
SMStephanie Renee Monticelli
Stephanie Renee Monticelli
YJYakin M Jaleta
Yakin M Jaleta
GLGorka Lasso
Gorka Lasso
MDMegan E DeMouth
Megan E DeMouth
EMEmily Happy Miller
Emily Happy Miller
Monkeypox virus (MPXV) has recently caused a global disease outbreak in humans. Differences in the neutralizing antibody response to vaccination versus MPXV infection remain poorly understood. Here, we examined the neutralization of MPXV and vaccinia virus by sera from a cohort of convalescent and vaccinated individuals at 1 and 8 months postexposure. Convalescent individuals displayed higher neutralizing antibody titers against MPXV than vaccinated and MPXV-naive persons at 1 month postexposure. Neutralizing antibody titers had waned significantly in both groups at 8 months. This study suggests that additional vaccine strategies are needed to elicit a durable humoral response and prevent breakthrough infections.

23 September 2024 in Research Square
Verified
Preprint
Open access
PDF file
Riccardo VernuccioRiccardo Vernuccio
Riccardo Vernuccio
ALAlejandro Martínez León
Alejandro Martínez León
Chetan PoojariChetan Poojari
Chetan Poojari
JBJulian Buchrieser
Julian Buchrieser
CSChristopher Selverian
Christopher Selverian
PGPablo Guardado-Calvo
Pablo Guardado-Calvo
Mpox is a zoonotic disease endemic in central and west Africa. However, since 2022, human-adapted mpox virus (MPXV) strains are causing large outbreaks spreading outside these regions, leading the World Health Organization to declare public health emergency twice. Tecovirimat, the most widely used drug to treat these infections, blocks viral egress through a poorly understood mechanism. Tecovirimat-resistant strains, all with mutations in the viral phospholipase F13, pose public health concerns. Herein, we report the structure of an F13 homodimer, both alone and in complex with tecovirimat. We demonstrate that tecovirimat acts as a molecular glue, inducing the dimerization of the phospholipase. F13 escape mutations in MPXV clinical isolates are at the dimer interface and prevent drug-induced dimerization in solution and cells. These findings, which decipher tecovirimat's mode of action, will allow better monitoring of poxvirus outbreaks and pave the way for developing more potent and resilient therapeutics.